

9 May 2022

SourceBio International plc
("SourceBio", the "Company" or the "Group")

**Posting of Annual Report and Accounts
and Notice of Annual General Meeting**

SourceBio International plc (AIM: SBI), a leading international provider of integrated state-of-the-art laboratory services and products, confirms that the Annual Report and Accounts for the year ended 31 December 2021 ("2021 Annual Report") and Notice of the 2022 Annual General Meeting ("AGM") have now been published on the Company's website at: <https://www.sourcebiointernational.com> (under Investor Relations, General Meetings section).

The 2021 Annual Report, and the Notice of AGM, which includes details of voting by proxy, will be posted to shareholders who have not consented to receive electronic communications.

The AGM is to be held on 15 June 2022 at midday at the Company's offices at 1 Orchard Place, Nottingham Business Park, Nottingham, NG8 6PX and will consider the resolutions set out in the Notice of AGM.

The minimum number of Directors who hold shares will be present, to form the necessary quorum. Regrettably, other shareholders will not be permitted to attend the meeting in person.

The Company will provide a facility for shareholders to listen in to the AGM either online or telephonically (in a non voting capacity) via the Investor Meet Company ("IMC") platform and there will be an opportunity for shareholders to ask questions. In order to facilitate the process, the Directors would request that shareholders register for the meeting and submit questions in advance, before 5pm on 11 June 2022. Investors can sign up for IMC for free and add to meet SourceBio International via:

<https://investormeetcompany.com/sourcebio-international-plc/register-investor>

Investors who have already registered for the IMC platform and added to meet the Company will be automatically invited.

Proxy voting

Shareholders wishing to vote on any of the matters of business are strongly encouraged to appoint the Chairman of the Meeting as their proxy. If you attempt to appoint a named individual other than the Chairman of the Meeting, such individual will not be permitted to attend the Meeting and you will instead be deemed to have appointed the Chairman of the Meeting as your proxy. Shareholders will receive a hard copy form of proxy for the 2022 AGM in the post and may also appoint a proxy by submitting a completed form of proxy to the Company's registrar online at sharevote.co.uk. Alternatively, shareholders are able to appoint a proxy via the CREST system. For your vote to be valid, please ensure it is received no later than midday on 13 June 2022. For more information on voting by proxy, including electronically or via CREST, please refer to the Explanatory Notes in the Notice of AGM.

Shareholders may request additional proxy forms directly from the Registrars, Equiniti, on Tel: 0371 384 2030 (+44 (0)121 415 7047 if calling from outside the UK). Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Shareholders wishing to appoint a proxy are strongly encouraged to appoint the Chairman of the Meeting as their proxy.

Contacts:

SourceBio International plc

Jay LeCoque, Executive Chairman
Tony Ratcliffe, Chief Financial Officer

www.sourcebiointernational.com

Via Walbrook PR

Liberum (Nominated Advisor and Broker)

Richard Lindley / William Hall

Tel: 020 3100 2000

Walbrook PR Limited

Paul McManus / Sam Allen

Tel: 020 7933 8780 or sourcebio@walbrookpr.com

Mob: 07980 541 893 / 07502 558 258

About SourceBio International plc www.sourcebiointernational.com

SourceBio is a leading international provider of integrated state-of-the-art laboratory services and products with clients in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four business units:

- **Healthcare Diagnostics** - histopathology cancer screening and clinical diagnostic services for the NHS and private healthcare providers across the UK and Ireland, including Digital Pathology
- **Genomics** - DNA sequencing services and Precision Medicine offering for pharmaceutical and biotechnology companies, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America
- **Stability Storage** - shelf-life testing services and equipment service and validation for pharmaceutical and biotechnology companies, contract manufacturers and analytical testing companies from around the world but primarily in the UK, Ireland and the USA
- **Infectious Disease Testing** - a range of COVID-19 testing services for commercial enterprises, private healthcare groups and the NHS, including PCR testing under ISO 15189 accreditation. SourceBio also provides employee testing solutions to industry, direct to consumer home test kits and venue testing.

More details on Group operations can be found here: www.sourcebioscience.com

SourceBio International plc (SBI) is listed on the AIM market of the London Stock Exchange.